TechMARK movers: Vectura data boost

Positive phase II data for its Parkinson's disease treatment has pushed up shares in Vectura. The VR040 treatment shows positive outcomes on the ability to control movement. This will help Vectura to licence the drug before phase II studies commence. Figures for the six months to September 2010 show a 15% increase in revenues to £26.3m and a sharply reduced loss of £600,000. There is £77.9m in the bank. Selling by Standard Life has hit the share price of software provider Micro Focus International. Standard Life was the second largest shareholder and it has been trimming its stake. The latest disposal has cut its stake from 9.91% to 7.68%. Drug developer ProStrakan has been hit by profit-taking after yesterday's announcement that it has received bid approaches. FTSE TechMARK - RisersVectura Group (VEC) 68.00p +5.84%Optos (OPTS) 103.00p +5.64%Oxford Biomedica (OXB) 9.74p +4.51%Oxford Instruments (OXIG) 512.00p +3.43%Sinclair Pharma (SPH) 31.00p +2.48%Computacenter (CCC) 379.00p +2.43%Aveva Group (AVV) 1,453.00p +2.40%BATM Advanced Communications Ltd. (BVC) 22.50p +2.27%Domino Printing Sciences (DNO) 526.00p +2.14%ARM Holdings (ARM) 356.60p +1.42%FTSE TechMARK - FallersNXT (NTX) 3.63p -9.25%Biocompatibles International (BII) 320.00p -5.04%Renovo Group (RNVO) 35.00p -4.76%ProStrakan Group (PSK) 91.25p -3.95%Antisoma (ASM) 6.25p -3.85%Micro Focus International Plc (MCRO) 326.50p -3.77%Vernalis (VER) 39.50p -3.66%KCOM Group (KCOM) 49.50p -2.94%Xaar (XAR) 214.00p -2.28%Innovation Group (TIG) 12.75p -1.92%